Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M202130200 on October 9, 2002

J. Biol. Chem., Vol. 277, Issue 50, 48427-48433, December 13, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/50/48427    most recent
M202130200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, G.
Right arrow Articles by Albert, P. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, G.
Right arrow Articles by Albert, P. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Growth Hormone-induced Diacylglycerol and Ceramide Formation via Galpha i3 and Gbeta gamma in GH4 Pituitary Cells

POTENTIATION BY DOPAMINE-D2 RECEPTOR ACTIVATION*

Gele Liu, Liliane Robillard, Behzad Banihashemi, and Paul R. AlbertDagger

From the Ottawa Health Research Institute, Neuroscience 451 Smyth Road, Room 2464, University of Ottawa, Ottawa, Canada K1H 8M5

Received for publication, March 4, 2002, and in revised form, October 3, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Growth hormone (GH) secretion is regulated by indirect negative feedback mechanisms. To address whether GH has direct actions on pituitary cells, lipid signaling in GH4ZR7 somatomammotroph cells was examined. GH (EC50 = 5 nM) stimulated diacylglycerol (DAG) and ceramide formation in parallel by over 10-fold within 15 min and persisting for >3 h. GH-induced DAG/ceramide formation was blocked by pertussis toxin (PTX) implicating Gi/Go proteins and was potentiated 1.5-fold by activation of Gi/Go-coupled dopamine-D2S receptors, which had no effect alone. Following PTX pretreatment, only PTX-resistant Galpha i3, not Galpha o or Galpha i2, rescued GH-induced DAG/ceramide signaling. GH-induced DAG/ceramide formation was also blocked in cells expressing Gbeta gamma blocker GRK-ct. In GH4ZR7 cells, GH induced phosphorylation of JAK2 and STAT5, which was blocked by PTX and mimicked by ceramide analogue C2-ceramide or sphingomyelinase treatment to increase endogenous ceramide. We conclude that in GH4 pituitary cells, GH induces formation of DAG/ceramide via a novel Galpha i3/Gbeta gamma -dependent pathway. This novel pathway suggests a mechanism for autocrine feedback regulation by GH of pituitary function.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Pituitary somatotrophs synthesize and secrete GH,1 which acts at the liver and other tissues to stimulate IGF formation, promoting somatic growth throughout the body (1, 2). Secretion of GH is stimulated by hypothalamic GH-releasing hormone and inhibited by the hypothalamic tetradecapeptide somatostatin and by IGF. In addition, somatostatin agonists (e.g. octreotide) and dopamine-D2 agonists (e.g. bromocryptine) are used clinically to treat acromegaly (a syndrome produced by hypersecretion of GH) and to inhibit somatomammotroph growth and GH production (3). Negative feedback via autocrine actions of GH at the pituitary has been postulated (4) but is yet to be clearly demonstrated.

The GH receptor is a member of the type I cytokine receptor superfamily, related to PRL and erythropoietin receptors that homodimerize to initiate signaling (5). The GH receptor signals through the JAK2 tyrosine kinase-signal transducer and activator of transcription 5 (STAT5) transcription factor pathway to induce gene expression (6-9). Phosphorylation on residue Tyr-694 by JAK2 is obligatory for STAT5 activation (10). The two STAT5 variants, STAT5a and STAT5b, have 90% identical protein sequences and are independently regulated and activated in various cell types (11). Studies using STAT5a or STAT5b knockout mice have demonstrated that STAT5b, but not STAT5a, is required for GH-induced regulation of IGF1 and sex-specific steroidogenic enzymes in liver (11-13). While STAT5 activation is implicated in many GH actions, other signaling pathways not involving STAT5 appear to be recruited for GH-induced stimulation of other pathways including MAPK phosphorylation and phosphatidyl inositol 3'-kinase or protein kinase C activation (14, 15) in a cell type-dependent manner (16).

Ceramide is a novel second messenger implicated in regulation of cell differentiation, proliferation, inflammation, and apoptosis (17-19). Ceramide plays an important role in signaling of a subgroup of cytokine receptors that includes tumor necrosis factor and interleukin-1 receptors (5, 15, 20, 21). However, the coupling of the GH/PRL-related family of receptors to ceramide has not been reported. We therefore examined whether GH might influence ceramide formation in pituitary cells as part of an autocrine feedback pathway and whether dopamine-D2 agonists would influence GH action.

Rat pituitary tumor GH4C1 cells synthesize and secrete PRL and GH and provide an excellent model of pituitary somatomammotrophs used for over 30 years (22). In this report we have identified a novel induction of DAG and ceramide formation by GH that is blocked by PTX, implicating the involvement of Gi/Go proteins (23). The contribution of specific Galpha subunits to GH autocrine signaling pathways was addressed using PTX-insensitive mutants of Galpha i2, Galpha i3, and Galpha o individually transfected into GH4ZR7 pituitary cells (GH4C1 cells transfected with the dopamine-D2S receptor (24, 25)). In PTX-insensitive G protein mutants, the carboxyl-terminal ribosyl-acceptor cysteine was changed to a nonacceptor serine. The Cys-to-Ser mutation is a structurally conservative change, and the mutant G proteins remain functional following PTX pretreatment (26-28). The role of Gbeta gamma subunits was evaluated by using the carboxyl-terminal domain of G protein-coupled receptor kinase (GRK-ct), a selective Gbeta gamma scavenger (29). In GH4ZR7 cells, dopamine-D2S receptor activation potentiated GH-induced DAG and ceramide formation. We have identified Galpha i3 and Gbeta gamma as crucial for both GH-induced ceramide formation and dopamine-D2-induced potentiation of the GH response.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Materials-- Apomorphine, dopamine, Staphylococcus aureus SMase, PTX, 1,2-dioleoyl-rac-glycerol (C18:1[cis]-9), DAG, puromycin, and all other drugs, standards, and salts were purchased from Sigma. Human GH (iodination grade) and Escherichia coli DAG kinase (13 units/mg protein) were from Calbiochem (San Diego, CA). Sera, media, and Geneticin (G418) were obtained from Invitrogen, Inc. [gamma -32P]ATP and [alpha -32P]dCTP (>3000 Ci/mmol) were from Amersham Biosciences. Thin-layer chromatography (TLC) plates (0.25 mm thick) were purchased from Whatman. Solvents were supplied by BDH. Plasmids pY3 and pCMV-LacZ II were obtained from the American Type Culture Collection (Manassas, VA). The cDNAs encoding wild-type rat Galpha o, Galpha i1, Galpha i2, and Galpha i3 were generously provided by Dr. Randall Reed, Johns Hopkins University, Baltimore, MD. Phospho-STAT5 (Tyr-694) antibody, phosphoplus® STAT3 (Tyr-705) and phosphoplus® p44/42 MAPK antibody kits were purchased from New England Biolabs (Mississauga, Ontario, Canada).

Plasmid Construction-- As previously described (27), PTX-insensitive Galpha i/o mutants were generated by point mutation of rat cDNAs (30) encoding Galpha i2 and Galpha i3 subunits at cysteine 351 (352 for Galpha i2). The TGT (cysteine codon) was mutated to TCT (serine) and confirmed by Sanger dideoxynucleotide sequencing. The mutant Galpha i2 and Galpha i3 cDNAs were FLAG-tagged at the initiator ATG codon, and the cDNAs were subcloned in KpnI-EcoRI-cut pcDNA3 (Invitrogen) to generate Galpha i2-PTX, Galpha i3-PTX, and Galpha o-PTX. The carboxyl-terminal domain of OK-GRK2 cDNA (31), beginning from Thr-493, was tagged at the amino-terminal with RGS-His6, and the His-GRK-ct fragment was cloned into pcDNA3 to produce the GRK-ct construct.

Cell Culture and Transfection-- GH4ZR7 cells and derivative clones were maintained in Ham's F10 medium with 8% fetal bovine serum (FBS) at 37 °C, 5% CO2. Galpha i2-PTX, Galpha i3-PTX, and Galpha o-PTX (20 µg) were cotransfected individually with pGK-puro (2 µg) into GH4ZR7 cells using calcium phosphate co-precipitation. The transfected cells were cultured in F10 + 8% FBS containing puromycin (20 µg/ml) for 3-4 weeks. Antibiotic-resistant clones were picked (24 clones/transfection) and tested for expression of the corresponding Galpha i/o proteins by Western blot analysis. The following Galpha i2-PTX, Galpha i3-PTX, Galpha o-PTX and GRK-ct clones were selected for analysis, respectively: Gi2Z 24, Gi3Z 15, Galpha o 15, and GRKZ 17. These cells express about 2- to 3-fold times the endogenous level of total Galpha protein in GH4ZR7 cells, suggesting that the ratio of PTX-insensitive/endogenous Galpha proteins in the clones was 1-2-fold (25).

Lipid Extraction-- Equivalent numbers of cells were cultured in ten 10-cm plates with Ham's F10 medium plus 8% FBS in a humidified atmosphere of 5% CO2, 95% air at 37 °C, grown to 80-90% confluence, and placed in serum-free F10 medium for 16 h. For PTX treatment, the cells were treated with 10 ng/ml PTX for 16 h prior to experimentation. Cells were rinsed with serum-free F10 medium and treated with experimental compounds at 37 °C as indicated. Following incubations, cells were twice rinsed with ice-cold PBS and lipids extracted (32). After centrifugation at 500 × g for 1 min at 4 °C, the supernatants were aspirated and the cells were lyzed with 0.5 ml of chloroform/methanol/HCl (20:40:1, v/v/v), and sonicated in 5-s intervals × 6 on ice. Cells were rinsed with 1 ml of chloroform and 0.3 ml of 1 M NaCl and spun at 14,000 × g for 15 min at 4 °C. The upper aqueous layer was discarded, and the lower lipid-containing layer was transferred to a 1-ml glass Chrompack vial, dried under a stream of O2-free N2 gas, and redissolved in 200 µl of chloroform. The samples were stored at -80 °C until analysis. The particulate protein interface was air-dried, dissolved in 0.5 ml of 2 M NaOH, and assayed for protein according to Lowry's method.

Quantification of DAG and Ceramide-- DAG and ceramide were quantified using the DAG kinase method (33, 34). A blank tube and a standard ceramide/DAG tube were included as controls. For each sample, 10 µl of DAG kinase (20 milliunits), 50 µl of reaction buffer (100 mM imidazole, pH 6.6, 25 mM MgCl2 and 2 mM EGTA), 10 µl of 20 mM dithiothreitol, and 10 µl of [gamma -32P]ATP (2.5 × 105 dpm/nmol) were added and incubated at 25 °C for 30 min, and the reactions terminated by addition of 0.5-ml ice-cold chloroform/methanol (1:2 v/v). The lipids were separated and extracted by addition of 0.5 ml of chloroform and 0.5 ml of 1 M NaCl spun at 14,000 × g for 3 min, and the upper aqueous phase was discarded. The organic phase was sequentially washed with 0.5 ml of 1% perchloric acid, 0.3 ml of chloroform/methanol (1:2 v/v), 0.2 ml of chloroform, and 0.2 ml of water, dried under N2, and reconstituted in 25 µl of chloroform/methanol (95:5, v/v). The samples were spotted onto a Silica Gel 60 TLC plate, heat-activated, and developed in a solvent mixture of chloroform/acetone/methanol/acetic acid/water (10:4:3:2:1, v/v/v/v/v). Since DAG kinase can use ceramide or DAG as substrate, [32P]ceramide-phosphate represented ceramide production and [32P]phosphatidic acid represented DAG production. The TLC plates were exposed to phosphor screens for 18 h, and [32P]ceramide-phosphate and [32P]phosphatidic acid were quantified using the Molecular Dynamics System ImageQuaNT computer software. Results are expressed as percentage of control.

GH Binding Assay-- The binding assay was performed using 50 µg of protein and 15,000 cpm/sample of 125I-hGH (2150 Ci/mmol, PerkinElmer Life Sciences) in a final volume of 300 µl (0.021 nM final concentration) of TME buffer (75 mM Tris, pH 7.4, 12.5 mM MgCl2, 1 mM EDTA) containing 0.1% BSA (35). To assess nonspecific binding 1 nM unlabeled hGH was added to the reaction. Incubation at room temperature was stopped after 30 min by the addition of 500 µl of cold 100 mM Tris, pH 7.4. The reaction was then filtered through GF/C filters and washed three times with 5 ml of cold 100 mM Tris, pH 7.4. Triplicate measurements were performed for all samples.

Western Blot Analysis-- Cells were treated as described above. Cell pellets were frozen on dry ice/ethanol and stored at -80 °C. Samples were sonicated 10-15 s, heated at 95 °C for 5 min, and centrifuged, and 40 µl/sample loaded onto SDS-PAGE gel and electrotransferred to polyvinylidene difluoride membrane. The membrane was blocked (1 h, room temperature), probed with primary antibody (1:1000, overnight, 4 °C), washed in TBST (10 mM Tris-HCl, pH 8, 150 mM NaCl, and 0.05% Tween 20) and incubated with horseradish peroxidase-conjugated secondary antibody (1:2000) and horseradish peroxidase-conjugated anti-biotin antibody (1:1000) to detect biotinylated protein markers (2 h at room temperature). The blot was then washed, incubated with LumiGLO (1 min), and exposed to x-ray film. Exposures in the linear range (gray scale) were scanned and quantified using the UnScanIt program (Silk Scientific Inc., Orem, Utah).

Statistical Analysis-- The data were analyzed by repeated measure using analysis of variance for each set of experiments. Differences of p < 0.05 were considered statistically significant.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Concentration- and Time-dependent Increase in DAG/Ceramide Formation Induced by GH-- The acute action of GH on endogenous DAG and ceramide levels in GH4ZR7 pituitary cells was assessed by the DAG kinase assay. The cells were washed to remove extracellular (secreted) GH and assayed in serum-free medium. GH induced a 10-fold increase in both DAG and ceramide production in a concentration-dependent manner from 10-10 to 10-6 M at 20 min with an EC50 of ~5 nM (Fig. 1). Addition of exogenous SMase (0.1 units/ml) was included as a positive control to demonstrate the hydrolysis of endogenous SM to form ceramide. The phosphorylated DAG and ceramide species co-migrated with the respective standards, confirming the identity of the products. GH (10-7 M) robustly increased both DAG and ceramide production in parallel, which was maximal within 15 min and declined but remained significantly elevated at 3 h (Fig. 2). Low levels of GH are secreted by GH4C1 cells at a rate of 0.2 ng/ml/min or 10-11 mol/liter/min (36), sufficient to reach a threshold concentration (10-9 M) for DAG/ceramide formation in 1.5 h following initiation of treatments (see "Materials and Methods"). However, GH is also metabolized, hence the actual GH concentration under culture conditions may be lower and did not appear to interfere with actions of exogenous GH.


View larger version (54K):
[in this window]
[in a new window]
 
Fig. 1.   Concentration-dependent GH-induced DAG and ceramide formation in GH4ZR7 cells. GH4ZR7 cells were treated with 10-10 to 10-6 M GH for 20 min. Lipids were extracted from cells, and [32P]phosphatidic acid and [32P]ceramide-phosphate were separated from other 32P-containing lipids by TLC to assay DAG and ceramide content, respectively. A representative image of [32P]phosphatidic acid and [32P]ceramide-phosphate is shown above. Below, the data are expressed as mean ± S.E. from three independent experiments. *, p < 0.05; **, p < 0.03; and ***, p < 0.01. B, blank; C, control; Std, standard.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 2.   Sustained GH-induced increases in DAG and ceramide production in GH4ZR7 cells. GH4ZR7 cells treated with 10-7 M GH for 15 min and 3 h. Lipids were extracted from cells and separated as described under "Material and Methods", and a representative image is shown. Below, the quantified data from three independent experiments are expressed as mean ± S.E. *, p < 0.03, and **, p < 0.01. B, blank; C, control; Std, standard.

PTX Blocks GH-induced Ceramide Production in GH4ZR7 Cells-- We recently showed that in Balb/c-3T3 fibroblasts, activation of the D2S receptor induces DAG and ceramide formation that is blocked by PTX, which inactivates Gi/Go proteins.2 Cells were pretreated with or without 10 ng/ml PTX for 16 h, a concentration that blocks Gi/Go-mediated signaling in these cells (22). PTX treatment blocked GH-induced DAG and ceramide formation, thus implicating Gi/Go proteins (Fig. 3). By contrast, PTX or dopamine-D2 agonist apomorphine (10-6 M) alone did not alter DAG or ceramide formation. Importantly, PTX treatment did not change the level of specific 125I-GH binding sites measured in crude membranes from GH4ZR7 cells. Specific 125I-GH binding was 118 ± 45 fmol/mg in GH4ZR7 cells (mean ± S.E., n = 3), and binding in PTX-treated cells was 104 ± 8% of control binding, indicating that blockade of GH-induced ceramide by PTX was not due to loss of receptor sites.


View larger version (59K):
[in this window]
[in a new window]
 
Fig. 3.   GH, but not apomorphine, induces PTX-sensitive DAG and ceramide production. GH4ZR7 cells were treated with 10-7 M GH or 10-6 M apomorphine with or without PTX pretreatment or treated with SMase 0.1 unit/ml, and a representative image of labeled DAG and ceramide products of the DAG kinase assay is shown. Below, the data are expressed as mean ± S.E. from three independent experiments. *, p < 0.03. A, apomorphine; B, blank; C, control; G, GH; P, PTX; S, SMase, or combinations as indicated.

Apomorphine Potentiates GH-induced DAG and Ceramide Production in GH4ZR7 Cells-- To examine further whether activation of the D2S receptor modulates DAG or ceramide formation, GH4ZR7 cells were incubated with GH, apomorphine (a D2 receptor agonist) or both GH and apomorphine (Fig. 4). Although dopamine-D2S receptor activation alone did not influence DAG or ceramide formation, apomorphine potentiated by 1.5- to 2-fold times the GH-induced formation of DAG and ceramide. In parental GH4C1 cells, which lack dopamine receptors, GH induced both DAG and ceramide formation but this effect was not enhanced by apomorphine (data not shown), indicating that apomorphine-induced potentiation is mediated via activation of dopamine-D2S receptors present on GH4ZR7 cells. Pretreatment with PTX blocked GH-induced ceramide production in GH4ZR7 and GH4C1 cells and also completely blocked DAG/ceramide production by apomorphine/GH (Fig. 5), indicating that D2S-induced potentiation of GH action involves Gi/Go proteins.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 4.   Potentiation of GH-induced DAG and ceramide formation by dopamine-D2 receptor activation. GH4ZR7 cells were treated with 10-7 M GH, 10-6 M apomorphine, both, or 0.1 unit/ml SMase for 20 min. Above, a representative image of [32P]phosphatidic acid and [32P]ceramide-phosphate is shown. Below, the data are expressed as mean ± S.E. from three independent experiments. *, p < 0.05; **, p < 0.03; and ***, p < 0.01. A, apomorphine; B, blank; C, control; G, GH; S, sphingomyelinase; Std, standard; or combinations as indicated.


View larger version (60K):
[in this window]
[in a new window]
 
Fig. 5.   Both GH- and apomorphine/GH-induced DAG and ceramide formation is blocked by PTX pretreatment. GH4ZR7 cells were treated as described in previous figures, and representative image of labeled DAG and ceramide products is shown above, and below averages of three experiments (mean ± S.E.), *, p < 0.03 and **, p < 0.01, compared with control. A: apomorphine; B: blank; C: control; G: GH; P: PTX; S: sphingomyelinase; Std: standard; or as indicated.

Rescue of GH-induced DAG and Ceramide Production by PTX-insensitive Galpha i3, but Not Galpha i2 or Galpha o and Involvement of Gbeta gamma Subunits-- We examined which subunit(s) of G proteins mediate DAG or ceramide signaling induced by GH or apomorphine/GH in combination using GH4ZR7 cells stably transfected with PTX-insensitive Galpha mutants (Galpha i2-PTX and Galpha i3-PTX cells) (25). As observed in wild-type GH4ZR7 cells and in Galpha i2-PTX and Galpha i3-PTX clones, the level of ceramide production induced by combination of apomorphine and GH was greater than for GH alone (Fig. 6 and data not shown). To examine the importance of Galpha i2-PTX and Galpha i3-PTX, cells were pretreated with PTX to block endogenous Gi/o proteins and challenged with GH or apomorphine/GH in combination. PTX blocked completely DAG and ceramide production stimulated by GH or apomorphine/GH in Galpha i2-PTX cells (Fig. 6). However in Galpha i3-PTX cells, both DAG and ceramide production were at least 50% resistant to PTX pretreatment (Fig. 7). Since ~50% of the total Galpha i3 was PTX-sensitive endogenous protein (25), a recovery of 50% of the response would be expected from the remaining fraction of PTX-insensitive Gi3 proteins. Thus Galpha i3, but not Galpha i2, plays a crucial role in both GH- and apomorphine/GH-induced DAG and ceramide formation. To examine the role of Galpha o subunits in GH-induced lipid signaling, GH4ZR7 cells were stably transfected with Galpha o-PTX. In these cells, PTX completely blocked DAG and ceramide formation induced by the combination of apomorphine and GH (Fig. 8), indicating that like Galpha i2-PTX, Galpha o-PTX does not rescue GH-induced lipid signaling.


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 6.   GH- or apomorphine/GH-induced DAG and ceramide formation is not rescued by Galpha i2-PTX. GH4ZR7 cells expressing PTX-insensitive Galpha i2 were treated as indicated in previous figures. Above is a representative image of DAG and ceramide product. Below, data are expressed as mean ± S.E. of three independent experiments. *, p < 0.05; **, p < 0.03.


View larger version (69K):
[in this window]
[in a new window]
 
Fig. 7.   Apomorphine/GH-induced DAG and ceramide formation is rescued by Galpha i3-PTX. GH4ZR7 cells expressing PTX-insensitive Galpha i3 cDNA were treated for 20 min with 10-6 M apomorphine or apomorphine and 10-7 M GH without or with PTX pretreatment (10 ng/ml, 16 h). Abbreviations are as in previous figures. Above is a representative image of labeled DAG and ceramide products, and below averaged data are expressed as mean ± S.E. *, p < 0.03 and **, p < 0.01.


View larger version (57K):
[in this window]
[in a new window]
 
Fig. 8.   Galpha o-PTX subunit fails to rescue DAG and ceramide signaling induced by combination of apomorphine and GH. GH4ZR7 cells expressing PTX-insensitive Galpha o were treated for 20 min with 10-6 M apomorphine or apomorphine and 10-7 M GH, without or with PTX pretreatment (10 ng/ml, 16 h). A representative image of labeled DAG and ceramide products is shown. Abbreviations are as in previous figures.

As a selective Gbeta gamma scavenger (29), the carboxyl-terminal domain of G protein-coupled receptor kinase (GRK-ct) was used to examine the role of Gbeta gamma subunits in signaling to ceramide formation. We have transfected GRK-ct into GH4ZR7 cells and identified expression of GRK-ct by Western blot (25). Neither apomorphine nor apomorphine/GH induced DAG or ceramide formation in GRK-ct cells (Fig. 9). This suggests that Gbeta gamma subunits are necessary for ceramide formation induced by the combination of apomorphine and GH.


View larger version (52K):
[in this window]
[in a new window]
 
Fig. 9.   GRK-ct blocks apomorphine/GH-induced DAG and ceramide formation. GH4ZR7 cells expressing the Gbeta gamma scavenger GRK-ct were treated for 20 min with 10-6 M apomorphine or apomorphine and 10-7 M GH, without or with PTX pretreatment (10 ng/ml, 16 h). A representative image of [32P]phosphatidic acid and [32P]ceramide-phosphate is shown. A, apomorphine; A+G, apomorphine + GH; B, blank; C, control; Std, standard.

GH and Ceramide Enhance JAK2/STAT5 Phosphorylation in GH4ZR7 Cells-- Based on the results above, we examined the influence of GH, apomorphine, PTX, and ceramide on well known and potential downstream pathways of the GH receptor including phosphorylation of JAK2, STAT5 (Fig. 10), STAT3 or MAPK. In GH4ZR7 cells, GH alone increased phosphorylation of JAK2 (100% increase over basal) and STAT5 (40% increase), which was more strongly enhanced with both apomorphine and GH (160% increase over basal for phospho-JAK2, 90% increase for phospho-STAT5). Treatment with a ceramide analogue (C2-ceramide) or SMase (to increase endogenous ceramide) also increased JAK2 phosphorylation by 90 and 150%, and STAT5 phosphorylation by 60 and 90%, respectively. Interestingly, PTX-blocked apomorphine/GH-induced STAT5 phosphorylation by 50%, further supporting a role for the PTX-sensitive ceramide pathway in GH-induced STAT5 phosphorylation in these cells. By contrast, these compounds elicited no changes in STAT3 or MAPK phosphorylation (data not shown).


View larger version (62K):
[in this window]
[in a new window]
 
Fig. 10.   PTX-sensitive regulation of JAK2/STAT5 by GH, apomorphine/GH, and C2-ceramide. GH4ZR7 cells were treated without (control, C) or with GH (10-7 M, G), apomorphine (10-6 M, A), both (A+G), C2-ceramide (5 µM, C2), or SMase (0.1 units/ml, S) for 30 min. Pretreatment with 10 ng/ml of PTX (P) was for 16 h. After harvesting cells, Western immunoblotting using antibodies to the indicated phospho-protein or beta -actin (loading control) was carried out. A, representative blots probed for phospho-JAK2 (p-JAK2), phospho-STAT5 (p-STAT5) and beta -actin as indicated. B and C, data from three independent experiments probed for phospho-JAK2 (B) or phospho-STAT5 (C) were quantified using the Un-Scan-It program and are presented as percent of control (mean ± S.E.); *, p < 0.03 and **, p < 0.01 compared with control.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

GH-induced Coupling to G Proteins and Lipid Signaling-- Our results indicate that GH induces a G protein-dependent increase in lipid metabolism to generate DAG and ceramide in GH4 cells. Previous studies in pre-adipocyte Ob1771 cells (37, 38) and in pancreatic beta -cells (39) have shown that GH induces DAG formation via activation of PC-PLC. By analogy, GH may activate PLC in GH4 cells to induce DAG formation. Both DAG and ceramide formation were induced in parallel, suggesting interconversion between these lipids possibly via SM synthase, which can convert DAG into ceramide, leading to depletion of SM (40, 41). Alternately, DAG can activate acidic SMase to generate ceramide (42, 43). Interconversion of DAG to ceramide would account for the identical Galpha i3 and Gbeta gamma dependencies of GH-mediated lipid formation.

The actions of GH in GH4 cells were sensitive to PTX pretreatment, indicating a role for Gi/Go proteins. Upon activation, GH receptors dimerize, associate with JAK2, and recruit a family of negative regulators, the SOCS (suppressors of cytokine signaling) proteins (44, 45). Coupling of the GH receptor to PTX-sensitive G proteins is relatively unexplored, and potential interactions of GH receptors or associated proteins such as SOCS proteins with G proteins remain elusive. There is some evidence that GH-like receptors interact with G proteins. In Nb2 cells, Galpha i proteins labeled by PTX-mediated ADP ribosylation were cross-linked to the PRL receptor using a 16-Å cross-linking agent, but not cross-linkers with shorter molecular lengths, consistent with a direct physical interaction (46). In addition, some PTX-sensitive GH-induced responses have been reported. For example, GH-induced PC-PLC activation in Ob1771 preadipocytes (37, 38) and GH-mediated DAG formation and mitogenesis in pancreatic beta -cells (39) are PTX-sensitive actions. Similarly, activation of the homologous PRL receptor in Nb2 lymphoma cells enhances PTX labeling of Gi proteins (suggesting activation) and induces PTX-sensitive mitogenesis (47-49). Taken together, these results are consistent with coupling of the GH receptor to PTX-sensitive Gi proteins to activate PLC thereby generating DAG, which can be converted to ceramide.

Although coupled to Gi/Go proteins, GH signaled differently from the Gi/Go-coupled dopamine D2 receptor to induce PTX-sensitive DAG and ceramide formation since apomorphine alone had no effect. Nevertheless there was an interaction between GH and D2 signaling since apomorphine potentiated GH-induced lipid signaling and JAK2/STAT5 activation. Furthermore, GH- and apomorphine/GH-induced DAG and ceramide formation were both rescued by Galpha i3-PTX and blocked by GRK-ct, suggesting a crucial role for Galpha i3/Gbeta gamma for both receptors. The dopamine-D2 receptor utilizes Gi3 to mediate activation of potassium channels in pituitary cells (50) via binding of Gbeta gamma to the GIRK potassium channel (51), and is likely to couple to Galpha i3/Gbeta gamma in GH4 pituitary cells. The mechanism by which GH receptors couple to Gi3 remains to be elucidated, but GH receptors appear to interact with Gi proteins differently from Gi-coupled heptahelical receptors (such as adenosine or D2S receptors). In adipocytes, GH prevented coupling of adenosine receptor-mediated inhibition of cAMP and activation of phosphatidylinositol-specific-PLC and blocked PTX-induced ADP-ribosylation (52, 53). GH may induce relocalization of Galpha i subunits, prevent their coupling to adenylyl cyclase (53, 54), and allow efficient coupling to DAG/ceramide formation. Since sites of ceramide synthesis display discrete subcellular localization (55), differences in the localization of D2S- and GH-receptor coupling might account for their differing effectiveness to induce ceramide formation in GH4 pituitary cells.

A Novel Pathway for GH-induced JAK2/STAT5 Activation-- Our data show that C2-ceramide and sphingomyelinase induce JAK2/STAT5 activation in GH4 cells, suggesting a link between GH-induced changes in DAG/ceramide and the classical GH-receptor-mediated JAK/STAT pathway. Consistent with our results, sphingomyelinase was shown to increase ceramide levels and was found to activate JAK2 and STAT1/3 in cultured human fibroblasts (56). Importantly, as observed for GH-mediated ceramide formation, GH-induced JAK2/STAT5 activation was enhanced by apomorphine and was partially blocked by PTX, suggesting that both G protein-dependent and -independent pathways lead to JAK2/STAT5 activation in these cells. Thus Gi-mediated ceramide signaling regulates GH-induced JAK2/STAT5 activation.

In addition to regulating JAK2/STAT5, GH-induced ceramide formation may activate other signaling cascades (19). Both GH (16, 57) and ceramide (19, 20) have been shown to activate the MAPK cascade in other cell types, but we observed no induction of p42/44-MAPK by either GH or ceramide in GH4 cells. Ceramide regulates other pathways including the SAPK/JNK cascade, and several proapoptotic pathways, but the roles of these pathways in GH4 cells is not known.

GH-mediated Autocrine Regulation of Pituitary Cells-- Multiple negative feedback pathways regulate GH secretion at the level of the hypothalamus and pituitary. At the level of the hypothalamus, GH inhibits GH-releasing hormone synthesis and enhances somatostatin release, resulting in decreased GH secretion at the pituitary (58-60). GH-induced IGF formation is believed to be the primary negative feedback pathway to inhibit GH synthesis in somatotrophs (1, 2). In addition, Gi/Go-coupled dopamine-D2 and somatostatin receptors also inhibit GH secretion and somatomammotroph growth (3). It is tempting to speculate that GH may negatively regulate its own secretion; however, evidence for a non-IGF-mediated autocrine pituitary feedback by GH is indirect (4, 61, 62). The GH receptor is expressed in rat and human anterior pituitary and binds and internalizes radiolabeled GH, suggesting a role for GH to regulate its secretion from the pituitary (63-66). However, the signaling of the GH receptor in pituitary cells has not been investigated. Our finding of a novel G protein-mediated action of GH to induce DAG/ceramide as well as JAK2/STAT5 activation in GH4 cells suggests a role for GH in regulation of pituitary function. GH4 cells are a pituitary cell strain that has provided an important model of somatotrophs that synthesize and secrete levels of GH that are sufficient to mediate autocrine GH-induced actions (22). Interestingly, C2-ceramide has been shown to inhibit GH secretion from rat anterior pituitary cells (67), suggesting that GH-induced ceramide formation could mediate negative feedback inhibition of GH secretion. Previously unexplored direct actions of GH on DAG and ceramide may provide a more sensitive method to address direct actions of GH in regulation of somatotroph function in vivo.

    FOOTNOTES

* This work was supported by The National Cancer Institute of Canada.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Holds the Novartis/Canadian Institutes for Health Research (CIHR) Michael Smith Chair in Neurosciences. To whom correspondence should be addressed. Tel.: 613-562-5800, ext.: 8307; Fax: 613-562-5403; E-mail: palbert@uottawa.ca.

Published, JBC Papers in Press, October 9, 2002, DOI 10.1074/jbc.M202130200

2 Liu, G., Robillard, L., Banihashemi, B., and Albert, P. R., in press.

    ABBREVIATIONS

The abbreviations used are: GH, growth hormone; IGF, insulin-like growth factor; DAG, diacylglycerol; PRL, prolactin; PTX, pertussis toxin; JAK, Janus kinase; STAT, signal transducing activator of transcription; SM, sphingomyelin; TLC, thin-layer chromatography; FBS, fetal bovine serum; PC-PLC, phosphatidyl choline phospholipase C.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Melmed, S., Yamashita, S., Yamasaki, H., Fagin, J., Namba, H., Yamamoto, H., Weber, M., Morita, S., Webster, J., and Prager, D. (1996) Rec. Prog. Horm. Res. 51, 189-215[Medline] [Order article via Infotrieve]
2. Giustina, A., and Veldhuis, J. D. (1998) Endocr. Rev 19, 717-797[Abstract/Free Full Text]
3. Colao, A., and Lombardi, G. (1998) Lancet 352, 1455-1461[CrossRef][Medline] [Order article via Infotrieve]
4. Asa, S. L., Coschigano, K. T., Bellush, L., Kopchick, J. J., and Ezzat, S. (2000) Am. J. Pathol. 156, 1009-1015[Abstract/Free Full Text]
5. Gadina, M., Hilton, D., Johnston, J. A., Morinobu, A., Lighvani, A., Zhou, Y. J., Visconti, R., and O'Shea, J. J. (2001) Curr. Opin. Immunol. 13, 363-373[CrossRef][Medline] [Order article via Infotrieve]
6. Kelly, P. A., Goujon, L., Sotiropoulos, A., Dinerstein, H., Esposito, N., Edery, M., Finidori, J., and Postel-Vinay, M. C. (1994) Horm. Res. 42, 133-139[Medline] [Order article via Infotrieve]
7. Herrington, J., Smit, L. S., Schwartz, J., and Carter-Su, C. (2000) Oncogene 19, 2585-2597[CrossRef][Medline] [Order article via Infotrieve]
8. Zhu, T., Goh, E. L., Graichen, R., Ling, L., and Lobie, P. E. (2001) Cell. Signal. 13, 599-616[CrossRef][Medline] [Order article via Infotrieve]
9. Herrington, J., and Carter-Su, C. (2001) Trends Endocrinol. Metab. 12, 252-257[CrossRef][Medline] [Order article via Infotrieve]
10. Gouilleux, F., Wakao, H., Mundt, M., and Groner, B. (1994) EMBO J. 13, 4361-4369[Medline] [Order article via Infotrieve]
11. Park, S. H., Liu, X., Hennighausen, L., Davey, H. W., and Waxman, D. J. (1999) J. Biol. Chem. 274, 7421-7430[Abstract/Free Full Text]
12. Davey, H. W., Xie, T., McLachlan, M. J., Wilkins, R. J., Waxman, D. J., and Grattan, D. R. (2001) Endocrinology 142, 3836-3841[Abstract/Free Full Text]
13. Davey, H. W., Park, S. H., Grattan, D. R., McLachlan, M. J., and Waxman, D. J. (1999) J. Biol. Chem. 274, 35331-35336[Abstract/Free Full Text]
14. Moutoussamy, S., Renaudie, F., Lago, F., Kelly, P. A., and Finidori, J. (1998) J. Biol. Chem. 273, 15906-15912[Abstract/Free Full Text]
15. Moutoussamy, S., Kelly, P. A., and Finidori, J. (1998) Eur. J. Biochem. 255, 1-11[Medline] [Order article via Infotrieve]
16. Love, D. W., Whatmore, A. J., Clayton, P. E., and Silva, C. M. (1998) Endocrinology 139, 1965-1971[Abstract/Free Full Text]
17. Liu, B., Obeid, L. M., and Hannun, Y. A. (1997) Semin. Cell Dev. Biol. 8, 311-322[CrossRef][Medline] [Order article via Infotrieve]
18. Basu, S., and Kolesnick, R. (1998) Oncogene 17, 3277-3285[CrossRef][Medline] [Order article via Infotrieve]
19. Liu, G., Kleine, L., and Hebert, R. L. (1999) Crit. Rev. Clin. Lab. Sci. 36, 511-573[CrossRef][Medline] [Order article via Infotrieve]
20. Raines, M. A., Kolesnick, R. N., and Golde, D. W. (1993) J. Biol. Chem. 268, 14572-14575[Abstract/Free Full Text]
21. Waters, M. J., Shang, C. A., Behncken, S. N., Tam, S. P., Li, H., Shen, B., and Lobie, P. E. (1999) Clin. Exp. Pharmacol. Physiol. 26, 760-764[CrossRef][Medline] [Order article via Infotrieve]
22. Albert, P. R. (1994) Vitam. Horm. 48, 59-109[Medline] [Order article via Infotrieve]
23. Birnbaumer, L. (1992) Cell 71, 1069-1072[CrossRef][Medline] [Order article via Infotrieve]
24. Albert, P. R., Neve, K. A., Bunzow, J. R., and Civelli, O. (1990) J. Biol. Chem. 265, 2098-2104[Abstract/Free Full Text]
25. Banihashemi, B., and Albert, P. R. (2002) Mol. Endocrinol. 16, 2393-2404[Abstract/Free Full Text]
26. Chuprun, J. K., Raymond, J. R., and Blackshear, P. J. (1997) J. Biol. Chem. 272, 773-781[Abstract/Free Full Text]
27. Ghahremani, M. H., Cheng, P., Lembo, P. M., and Albert, P. R. (1999) J. Biol. Chem. 274, 9238-9245[Abstract/Free Full Text]
28. Ghahremani, M. H., Forget, C., and Albert, P. R. (2000) Mol. Cell. Biol. 20, 1497-1506[Abstract/Free Full Text]
29. Koch, W. J., Hawes, B. E., Inglese, J., Luttrell, L. M., and Lefkowitz, R. J. (1994) J. Biol. Chem. 269, 6193-6197[Abstract/Free Full Text]
30. Jones, D. T., and Reed, R. R. (1987) J. Biol. Chem. 262, 14241-14249[Abstract/Free Full Text]
31. Lembo, P. M., Ghahremani, M. H., and Albert, P. R. (1999) Mol. Endocrinol. 13, 138-147[Abstract/Free Full Text]
32. Bligh, E. G., and Dyer, W. J. (1959) Can. J. Biochem. Physiol. 37, 911-917[Medline] [Order article via Infotrieve]
33. Preiss, J., Loomis, C. R., Bishop, W. R., Stein, R., Niedel, J. E., and Bell, R. M. (1986) J. Biol. Chem. 261, 8597-8600[Abstract/Free Full Text]
34. Wright, T. M., Rangan, L. A., Shin, H. S., and Raben, D. M. (1988) J. Biol. Chem. 263, 9374-9380[Abstract/Free Full Text]
35. Klempt, M., Bingham, B., Breier, B. H., Baumbach, W. R., and Gluckman, P. D. (1993) Endocrinology 132, 1071-1077[Abstract/Free Full Text]
36. Albert, P. R., and Tashjian, A. H., Jr. (1984) J. Biol. Chem. 259, 15350-15363[Abstract/Free Full Text]
37. Doglio, A., Dani, C., Grimaldi, P., and Ailhaud, G. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 1148-1152[Abstract/Free Full Text]
38. Catalioto, R. M., Ailhaud, G., and Negrel, R. (1990) Biochem. Biophys. Res. Commun. 173, 840-848[CrossRef][Medline] [Order article via Infotrieve]
39. Sjoholm, A., Zhang, Q., Welsh, N., Hansson, A., Larsson, O., Tally, M., and Berggren, P. O. (2000) J. Biol. Chem. 275, 21033-21040[Abstract/Free Full Text]
40. van Helvoort, A., van't Hof, W., Ritsema, T., Sandra, A., and van Meer, G. (1994) J. Biol. Chem. 269, 1763-1769[Abstract/Free Full Text]
41. Luberto, C., and Hannun, Y. A. (1998) J. Biol. Chem. 273, 14550-14559[Abstract/Free Full Text]
42. Schutze, S., Machleidt, T., and Kronke, M. (1994) J. Leukoc. Biol. 56, 533-541[Abstract]
43. Schutze, S., Wiegmann, K., Machleidt, T., and Kronke, M. (1995) Immunobiology 193, 193-203[Medline] [Order article via Infotrieve]
44. Finidori, J. (2000) Vitam. Horm. 59, 71-97[Medline] [Order article via Infotrieve]
45. Ram, P. A., and Waxman, D. J. (1999) J. Biol. Chem. 274, 35553-35561[Abstract/Free Full Text]
46. Too, C. K., Shiu, R. P., and Friesen, H. G. (1990) Biochem. Biophys. Res. Commun. 173, 48-52[CrossRef][Medline] [Order article via Infotrieve]
47. Larsen, J. L., and Dufau, M. L. (1988) Endocrinology 123, 438-444[Abstract/Free Full Text]
48. Too, C. K., Murphy, P. R., and Friesen, H. G. (1989) Endocrinology 124, 2185-2192[Abstract/Free Full Text]
49. Larsen, J. L. (1992) J. Biol. Chem. 267, 10583-10587[Abstract/Free Full Text]
50. Lledo, P. M., Homburger, V., Bockaert, J., and Vincent, J. D. (1992) Neuron 8, 455-463[CrossRef][Medline] [Order article via Infotrieve]
51. Clapham, D. E., and Neer, E. J. (1997) Annu. Rev. Pharmacol. Toxicol. 37, 167-203[CrossRef][Medline] [Order article via Infotrieve]
52. Roupas, P., Chou, S. Y., Towns, R. J., and Kostyo, J. L. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 1691-1695[Abstract/Free Full Text]
53. Doris, R. A., Kilgour, E., Houslay, M. D., and Vernon, R. G. (1998) J. Endocrinol. 158, 295-303[Abstract]
54. Yip, R. G., and Goodman, H. M. (1999) Endocrinology 140, 1219-1227[Abstract/Free Full Text]
55. Hannun, Y. A., and Obeid, L. M. (2002) J. Biol. Chem. 277, 25847-25850[Free Full Text]
56. Maziere, C., Conte, M. A., and Maziere, J. C. (2001) FEBS Lett. 507, 163-168[CrossRef][Medline] [Order article via Infotrieve]
57. Yarwood, S. J., Sale, E. M., Sale, G. J., Houslay, M. D., Kilgour, E., and Anderson, N. G. (1999) J. Biol. Chem. 274, 8662-8668[Abstract/Free Full Text]
58. Peng, X. D., Park, S., Gadelha, M. R., Coschigano, K. T., Kopchick, J. J., Frohman, L. A., and Kineman, R. D. (2001) Endocrinology 142, 1117-1123[Abstract/Free Full Text]
59. Kamegai, J., Unterman, T. G., Frohman, L. A., and Kineman, R. D. (1998) Endocrinology 139, 3554-3560[Abstract/Free Full Text]
60. Zheng, H., Bailey, A., Jiang, M. H., Honda, K., Chen, H. Y., Trumbauer, M. E., Van der Ploeg, L. H., Schaeffer, J. M., Leng, G., and Smith, R. G. (1997) Mol. Endocrinol. 11, 1709-1717[Abstract/Free Full Text]
61. Nakamoto, J. M., Gertner, J. M., Press, C. M., Hintz, R. L., Rosenfeld, R. G., and Genel, M. (1986) J. Clin. Endocrinol. Metab. 62, 822-826[Abstract/Free Full Text]
62. Ross, R. J., Borges, F., Grossman, A., Smith, R., Ngahfoong, L., Rees, L. H., Savage, M. O., and Besser, G. M. (1987) Clin. Endocrinol. 26, 117-123[Medline] [Order article via Infotrieve]
63. Mertani, H. C., Pechoux, C., Garcia-Caballero, T., Waters, M. J., and Morel, G. (1995) J. Clin. Endocrinol. Metab. 80, 3361-3367[Abstract]
64. Mertani, H. C., Waters, M. J., Jambou, R., Gossard, F., and Morel, G. (1994) Neuroendocrinology 59, 483-494[Medline] [Order article via Infotrieve]
65. Harvey, S., Baumbach, W. R., Sadeghi, H., and Sanders, E. J. (1993) Endocrinology 133, 1125-1130[Abstract/Free Full Text]
66. Fraser, R. A., Siminoski, K., and Harvey, S. (1991) J. Endocrinol. 128, R9-R11[Abstract/Free Full Text]
67. Negishi, T., Chik, C. L., and Ho, A. K. (1999) Endocrinology 140, 5691-5697[Abstract/Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
DiabetesHome page
A. C.P. Thirone, L. JeBailey, P. J. Bilan, and A. Klip
Opposite Effect of JAK2 on Insulin-Dependent Activation of Mitogen-Activated Protein Kinases and Akt in Muscle Cells: Possible Target to Ameliorate Insulin Resistance.
Diabetes, April 1, 2006; 55(4): 942 - 951.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
N. D. Khoa, M. Postow, J. Danielsson, and B. N. Cronstein
Tumor Necrosis Factor-{alpha} Prevents Desensitization of G{alpha}s-Coupled Receptors by Regulating GRK2 Association with the Plasma Membrane
Mol. Pharmacol., April 1, 2006; 69(4): 1311 - 1319.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
Z. Wu, R. Tandon, J. Ziembicki, J. Nagano, K. M. Hujer, R. T. Miller, and C. Huang
Role of ceramide in Ca2+-sensing receptor-induced apoptosis
J. Lipid Res., July 1, 2005; 46(7): 1396 - 1404.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/50/48427    most recent
M202130200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, G.
Right arrow Articles by Albert, P. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, G.
Right arrow Articles by Albert, P. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement